CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
TAK-418 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03228433
NCT03228433Phase 1Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled, Ascending Oral Single Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-418 in Healthy Subjects

Takeda·interventional·Posted Jul 24, 2017·Updated Sep 9, 2019

In Brief

A Phase 1 clinical trial evaluating TAK-418 and TAK-418 Placebo for Healthy Participants. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety and tolerability of TAK-418 following single oral doses in healthy participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedJul 24, 2017
Enrollment StartJul 21, 2017
Primary CompletionMay 12, 2018
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 8.9 years ago

Interventions

TAK-418drug

TAK-418 Capsule.

TAK-418 Placebodrug

TAK-418 placebo-matching capsules.